As Oncoheroes prepares to evaluate the efficacy of its lead compound, volasertib, across five pediatric cancer indications, including rhabdomyosarcoma, the Super Sam Foundation once again steps forwar...
This alliance will drive research in pediatric cancer epigenetics, through access to IRB Barcelona's top-notch infrastructure, with the ultimate goal of translating this innovative knowledge into tang...
As many other events this year, Bio Investors Forum (Oct 13-15) is going remote. This is a unique opportunity where international biotech investor meet with early and established private companies as ...
The Spanish Platform for Nanomedicine (NanoMedSpain) coordinated by Josep Samitier, director of IBEC, has participated once again in the Annual Conference of Technological Platforms of Biomedical Rese...
Ability Pharmaceuticals today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the ...